# C. Zhou

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/c-zhou/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,431 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 12 |
| i10-index | 13 |
| Last Known Institution | Shanghai Jiao Tong University |
| OpenAlex ID | https://openalex.org/A5054464962 |
| ORCID iD | 0009-0001-9269-6222 |
| Works | 118 |

## Researcher papers

- [Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)](https://scholariq.org/papers/final-overall-survival-results-from-a-randomised-phase-iii-study-of-erlotinib/)
- [Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study](https://scholariq.org/papers/mechanisms-of-acquired-resistance-to-first-line-osimertinib-preliminary-data/)
- [Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer](https://scholariq.org/papers/metformin-reprograms-tryptophan-metabolism-to-stimulate-cd8-t-cell-function-in/)
- [ROS1 fusions in Chinese patients with non-small-cell lung cancer](https://scholariq.org/papers/ros1-fusions-in-chinese-patients-with-non-small-cell-lung-cancer/)
- [2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC](https://scholariq.org/papers/2o-impower010-biomarkers-of-disease-free-survival-dfs-in-a-phase-iii-study-of/)
- [Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis](https://scholariq.org/papers/osimertinib-vs-comparator-egfr-tki-as-first-line-treatment-for-egfrm-advanced/)
- [CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study](https://scholariq.org/papers/cns-response-to-osimertinib-vs-standard-of-care-soc-egfr-tki-as-first-line/)
- [OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations](https://scholariq.org/papers/oa04-03-mobocertinib-in-nsclc-with-egfr-exon-20-insertions-results-from-exclaim/)
- [1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results](https://scholariq.org/papers/1194mo-canakinumab-can-docetaxel-dtx-for-the-second-or-third-line-2-3l-treatment/)
- [OA04.03 A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer](https://scholariq.org/papers/oa04-03-a-randomized-phase-3-study-of-camrelizumab-plus-chemotherapy-as-1st-line/)
- [P1.01-22 Investigation of Acquired Resistance for EGFR-TKI Plus Bevacizumab as 1st Line Treatment in Patients with EGFR Sensitive Mutant NSCLC](https://scholariq.org/papers/p1-01-22-investigation-of-acquired-resistance-for-egfr-tki-plus-bevacizumab-as/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Cancer, Stress, Anesthesia, and Immune Response](https://scholariq.org/topics/cancer-stress-anesthesia-and-immune-response/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [Shanghai Jiao Tong University](https://scholariq.org/institutions/shanghai-jiao-tong-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.